These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28643803)

  • 41. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 43. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
    Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
    Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis.
    Dong B; Gao Y; Kang X; Gao H; Zhang J; Guo H; You MJ; Xue W; Cheng J; Huang Y
    Oncotarget; 2016 Dec; 7(49):80435-80449. PubMed ID: 27741516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma.
    Ricketts CJ; Linehan WM
    Cancer Discov; 2017 Nov; 7(11):1221-1223. PubMed ID: 29097620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
    Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
    Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
    Qi H; Ohh M
    Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.
    Huang Q; Sun Y; Zhai W; Ma X; Shen D; Du S; You B; Niu Y; Huang CP; Zhang X; Chang C
    Oncogene; 2020 Oct; 39(43):6677-6691. PubMed ID: 32943729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
    Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
    Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
    Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
    Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
    Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypoxia-inducible factor 1α mediates the down-regulation of superoxide dismutase 2 in von Hippel-Lindau deficient renal clear cell carcinoma.
    Gao YH; Li CX; Shen SM; Li H; Chen GQ; Wei Q; Wang LS
    Biochem Biophys Res Commun; 2013 May; 435(1):46-51. PubMed ID: 23611775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.